ReviewHuman vaccines & immunotherapeutics2014
A capsule conjugate vaccine approach to prevent diarrheal disease caused by Campylobacter jejuni.
Review in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06122870 (Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of CampETEC Hyperimmune Bovine Colostrum), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of CampETEC Hyperimmune Bovine Colostrum (HBC) for the Prevention of Campylobacter-Mediated Diarrheal Diseases
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Design of Innovative Divalent Cj1621 and CjaA Multiepitope mRNA-Based Vaccine Against FoodborneVeterinary medicine international · 2025Article
- Effect of the polysaccharide capsule and its heptose on the resistance of Campylobacter jejuni to innate immune defenses.MicrobiologyOpen · 2024Article
- Campylobacter vaccination reduces diarrheal disease and infant growth stunting among rhesus macaques.Nature communications · 2023Article
- Pan-Genome Analysis of Campylobacter: Insights on the Genomic Diversity and Virulence Profile.Microbiology spectrum · 2022Article
- Vaccines for Protecting Infants from Bacterial Causes of Diarrheal Disease.Microorganisms · 2021Review
- Vaccine-mediated protection againstScience advances · 2020Article
- Novel ClinicalMicroorganisms · 2020Review
- The effectiveness of a dietary direct-fed microbial and mannan oligosaccharide on ultrastructural changes of intestinal mucosa of turkey poults infected with Salmonella and Campylobacter.Poultry science · 2020Article
- Evaluations of Alkyl hydroperoxide reductase B cell antigen epitope as a potential epitope vaccine againstSaudi journal of biological sciences · 2019Article
- Antibiotic resistance, molecular characterizations, and clinical manifestations of Campylobacteriosis at a military medical center in Hawaii from 2012-2016: a retrospective analysis.Scientific reports · 2018Article
- Capsular genotype and lipooligosaccharide locus class distribution in Campylobacter jejuni from young children with diarrhea and asymptomatic carriers in Bangladesh.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Article
- Epidemiology ofThe American journal of tropical medicine and hygiene · 2018Article
- Key Role of Capsular Polysaccharide in the Induction of Systemic Infection and Abortion by Hypervirulent Campylobacter jejuni.Infection and immunity · 2017Article
- From Immunologically Archaic to Neoteric Glycovaccines.Vaccines · 2017Review
- Current and Potential Treatments for ReducingFrontiers in microbiology · 2017Review
- Chicken Anti-Campylobacter Vaccine - Comparison of Various Carriers and Routes of Immunization.Frontiers in microbiology · 2016Article
- Article
- Update on the burden of Campylobacter in developing countries.Current opinion in infectious diseases · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Campylobacter jejuni is a major cause of diarrheal disease and results in high levels of morbidity and economic loss in both industrialized and developing regions of the world. To date, prior vaccine approaches have failed to confer protection against this enteric pathogen. Key challenges to the development of a practical Campylobacter vaccine for human use include a lack of understanding of Campylobacter pathogenesis and well-defined immune correlates of protection. With the discovery that C. jejuni expresses a capsule polysaccharide associated with virulence, a conjugate vaccine approach is currently being evaluated. Conjugate vaccines have been successfully developed and implemented against other invasive mucosal pathogens including Streptococcus pneumoniae, Neisseria meningitidis, and Hemophilus influenzae. Furthermore, Shigella-based conjugate vaccines based on lipopolysaccharide have shown promising results in field trials. A prototype C. jejuni conjugate vaccine is currently entering human testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.